Table 1 Presenting features and clinical course information among ten patients with chronic phase chronic myeloid leukemia (CP-CML) harboring sole BCR::ABL1 e1a2 (P190) transcripts.

From: Chronic phase CML with sole P190 (e1a2) BCR::ABL1: long-term outcome among ten consecutive cases

Variables

All patients (n = 10)

Age in years at diagnosis; median (range)

63 (50–83)

Females, n (%)

6 (60)

Leukocytes × 109/L; median (range)

58 (19.3–175)

Absolute monocyte count × 109/L; median (range)

7 (0.8–29.6)

Blood monocyte %; median (range)

12 (3–21)

Absolute eosinophil count × 109/L; median (range)

0.8 (0.3–8.4)

Blood eosinophil %; median (range)

2 (1–7)

Absolute basophil count × 109/L; median (range)

0.9 (0.06-4.2)

Blood basophil %; median (range)

2.5 (0.46-5)

Absolute myelocyte count × 109/L; median (range)

3.3 (0-29.7)

Blood myelocyte %; median (range)

5.5 (0-3)

Blood blast count × 109/L; median (range)

0.9 (0-4)

Blood blast %; median (range)

1 (0-2)

Bone marrow blast %; median (range)

1 (0–2)

Bone marrow reticulin fibrosis grade; median (range)

0 (0-1)

Hemoglobin g/dL; median (range)

12.5 (10–14.4)

Platelets × 109/L; median (range)

209 (118–479)

Philadelphia chromosome karyotype at time of diagnosis, n (%)

100%

No. of metaphases analyzed; median (range)

20 (20–25)

Metaphases involved, (n)

 100%

7

 80%

1

 35%

2

Palpable splenomegaly, n (%)

2 (20)

Symptoms at time of diagnosis seen in 2 or more patients:

 Asymptomatic, n (%)

5 (50)

 Fatigue, n (%)

3 (30)

 Abdominal discomfort, n (%)

2 (20)

Tyrosine Kinase Inhibitor response at any time:

Complete hematologic response (CHR), n (%)

10 (100)

Complete cytogenetic response (CCyR), n (%)

8 (80)

Major molecular response (MMR), n (%)

5 (50)

Follow-up period from diagnosis in years; median (range)

6 (1–16)

Deaths, n (%)

Both deaths were unrelated to CML

2 (20)

Progression to Acute Myeloid Leukemia, n (%)

0 (0)

Allogeneic hematopoietic stem cell transplant, n (%)

0 (0)

Back to article page